Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development

The Wall Street JournalView source article

Part of story

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.

Nov 11, 20263 sourcesClinical trials Weight loss drugs GLP-1 receptor agonists Drug development GLP-1 Pharmaceutical Industry Private equity Obesity treatment

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Other sources for this story

Reuters

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development | Reuters

Bloomberg

Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development

Part of story

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Other sources for this story

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development | Reuters

Blackstone Puts Up $1.5 Billion for Pfizer Obesity Drug Studies

Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development

Part of story

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Other sources for this story

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development | Reuters

Blackstone Puts Up $1.5 Billion for Pfizer Obesity Drug Studies